TABLE 1.
Immunoassays for Cerebrospinal Fluid Total Tau, Phospho-Tau and β-Amyloid (Aβ42)
| Type of Method | Ref. | Specificity | Antibodies | Mean Change (% of controls) |
|---|---|---|---|---|
| Total tau | ||||
| ELISA | 13 | Total tau | AT120 + PAb | Increase |
| ELISA | 14 | Total tau | AT120 + HT7/BT2 | Increase (mean ≈ 300%)17 |
| ELISA | 15 | Total tau | 16B5 + 16G7 | Increase (mean ≈ 200%)17 |
| Microsphere ELISA | 16 | Total tau | PAb-ht2 + MAbs F-F11/F-H5 | Increase (216%) |
| Phospho-tau | ||||
| ELISA | 14 | P-Thr181 + P-Thr231 | AT180/AT270 + HT7/AT120 | Increase (348%) |
| ELISA | 22 | P-Thr231 + P-Ser235 | MAb anti-tau + anti-PT231PS235 | Increase (no mean level given) |
| ELISA | 22 | P-Ser199 | MAb anti-tau + anti-PS199 | Increase (≈ 2–300%)86,93 |
| ELISA | 23 | P-Thr231 | Tau1/CP27 + CP9 | Increase |
| ELISA | 21 | P-Thr181 | HT7 + AT270 | Increase (≈ 2–300%)26,93 |
| ELISA | 24 | P-Ser396 + P-Ser404 | PAb92e + PHF-1 | Increase (346%) |
| β-amyloid | ||||
| ELISA | 39 | Aβ 1–42 | BAN-50 + BC-05 | Decrease (mean ≈ 50%)17 |
| ELISA | 41 | Aβ 1–42 | 21F12 + 3D6 | Decrease (mean ≈ 50%)17 |
| ELISA | 35 | Aβ X-42 | 266 + PAb 277–2 | Decrease (mean ≈ 50%)17 |
| ELISA | 39 | Aβ X-42 | BNT-77 + BC-05 | Decrease (mean ≈ 50%)17 |
| ELISA | 46 | Aβ X-42 | WO-2 + G2–11 | Increase (161%) |
| ELISA | 42 | Aβ X-42 | 6E10 + PAb164 | Decrease (32%) |
| ELISA | 43 | Aβ X-42 | 4G8 + PAb44–344 | Decrease (37%) |
| Western blot | 44 | Aβ X-42 | G2–11 | Decrease (43%) |
| Immunoprecipitation + Western blot | 45 | Aβ X-42 | G2–11 | Decrease (39%) |
| Urea SDS-PAGE + Western blot | 47 | Aβ 1–42 | n.a. | Decrease (50%) |
| SELDI-TOF | 48 | Aβ 1–42 | n.a. | Decrease (71%) |
Ref. = reference number; PAb = polyclonal antibody; MAb = monoclonal antibody; Thr = threonine; Ser = serine; n.a. = not applicable; SELDI-TOF = surface-enhanced laser desorption ionization time-of-flight masspectrometry.